CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Ciclesonide Metered Dose Inhaler [Alvesco]Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug360 Hydroxychloroquine Wiki 0.13

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.30

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19

According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide alone or in combination with hydroxychloroquine could eradicate SARS-CoV-2 from respiratory tract earlier in patients with mild COVID-19.

NCT04330586 COVID-19 Drug: Ciclesonide Metered Dose Inhaler [Alvesco] Drug: Hydroxychloroquine

Primary Outcomes

Description: Viral load

Measure: Rate of SARS-CoV-2 eradication at day 14 from study enrollment

Time: Hospital day 14

Secondary Outcomes

Description: Viral load

Measure: Rate of SARS-CoV-2 eradication at day 7 from study enrollment

Time: Hospital day 7

Description: Viral load

Measure: Time to SARS-CoV-2 eradication (days)

Time: Hospital day 1, 4, 7, 10, 14, 21

Description: Viral load change

Measure: Viral load area-under-the-curve (AUC) reduction versus control

Time: Hospital day 1, 4, 7, 10, 14, 21

Description: Resolution of all systemic and respiratory symptoms for ≥2 consecutive days

Measure: Time to clinical improvement (days)

Time: Up to 28 days

Description: ICU admission, mechanical ventilation or death

Measure: Proportion of clinical failure

Time: Up to 28 days

Other Outcomes

Description: Number of adverse events, proportion of early discontinuance

Measure: Safety and tolerability of study drug

Time: Up to 28 days


No related HPO nodes (Using clinical trials)